Unlike aBC where the objective of the treatment is to delay progression and prolong life, the goal of eBC treatment is to cure the patient.1,2 

References: 1 and 2

Treatment for breast cancer can be broadly classified into local or systemic therapy.3

References: 3 and 4

Multiple factors drive treatment decisions for eBC.3

References: 3

Endorcrine-based systemic therapy is a standard component of HR+/HER2-eBC treatment, regardless of if CT is indicated or not.4

References: 4

Adjuvant systemic therapies for HR+/HER2- breast cancer include:

References: 4, 5, 6, and 7

CDK 4/6, cyclin-dependent kinase 4/6; eBC, early breast cancer; gBRCA, germline breast cancer gene;
HER2, human epidermal growth factor receptor 2; HR, hormone receptor; PARP, poly-ADP ribosepolymeras

  1. Irvin W, Muss HB, Mayer DK. Symptom management in metastatic breast cancer. Oncologist. 011;16(9):1203-1214.
  2. Scharl A, Kühn T, Papathemelis T, et al. The Right Treatment for the Right Patient - Personalised Treatment of Breast Cancer. Geburtshilfe Frauenheilkd. 2015;75(7):683-691.
  3. Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019;30(8):1194-1220.
  4. American Cancer Society (ACS). Treating Breast Cancer. Atlanta, GA: January 2023:1-115.
  5. National Cancer Institute (NCI). NCI Dictionary of Cancer Terms. Bethesda, MD: U.S. National Institutes of Health (NIH); 2023.
  6. AstraZeneca. Press release. August 4, 2022.
  7. Tung N, Garber JE. PARP inhibition in breast cancer: progress made and future hopes. NPJ Breast Cancer. 2022;8(1):47.

Ask the speakers